Literature DB >> 19344920

Severe demyelinating hypertrophic polyneuropathy caused by a de novo frameshift mutation within the intracellular domain of myelin protein zero (MPZ/P0).

Jana Zschüntzsch1, Payam Dibaj, Sara Pilgram, Judith Kötting, Wanda M Gerding, C Neusch.   

Abstract

Hereditary motor and sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth disease (CMT) is a group of clinically and genetically heterogeneous neuropathies classically divided into demyelinating (CMT1) and axonal forms (CMT2). The most common demyelinating form is CMT1A with an underlying duplication in the gene coding for the peripheral myelin protein 22 (PMP22). Less frequently, mutations in the myelin protein zero gene (MPZ/P(0)) account for demyelinating CMT1B, Dejerine-Sottas syndrome (DSS), or congenital hypomyelinating neuropathy (CHN). Here, we report a patient with a severe, early-onset hypertrophic and dysmyelinating neuropathy. The patient exhibits a novel frameshift mutation with an insertion of a single T-nucleotide on position c.618_619 of the MPZ gene resulting in a premature stop M207fsX38.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344920     DOI: 10.1016/j.jns.2009.03.008

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  MR imaging of demyelinating hypertrophic polyneuropathy.

Authors:  Julie Rowin
Journal:  Neurology       Date:  2010-04-06       Impact factor: 9.910

2.  Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype.

Authors:  Ilaria Callegari; C Gemelli; A Geroldi; F Veneri; P Mandich; M D'Antonio; D Pareyson; M E Shy; A Schenone; V Prada; M Grandis
Journal:  J Neurol       Date:  2019-07-05       Impact factor: 4.849

Review 3.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.